Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Intensity Therapeutics Q3 2026 Results: Net Loss of $3.54M, Loss Widens

Intensity Therapeutics reported a net loss of $9.0 million for the nine months ended September 30, 2026, compared to $8.6 million in the prior year period. The company's cash position decreased to $8.5 million from $11.9 million at year-end 2025, primarily due to ongoing research and development expenses for its lead drug candidate, INT230-6.

Watch the Intensity Therapeutics, Inc. earnings callFull call on the ALFA USA YouTube channel
Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-3.5-2.7
EPS (diluted, $ a share)$-1.09$-1.55

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: INTS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Intensity Therapeutics, Inc.: key numbers

Share price
$3.07Close, Nov 16
Market cap
$10.1M
Shares outstanding
3.3MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Intensity Therapeutics, Inc.

All →
7:55 AM ET 8-K
Business Update

Intensity Therapeutics Business Update

Intensity Therapeutics reported its Q3 2026 financial results and provided an operational update on its clinical pipeline, including the resumption of patient enrollment in the Phase 3 INVINCIBLE-3 soft tissue sarcoma study and the Phase 2 INVINCIBLE-4 triple-negative breast cancer study. The company ended the quarter with $8.5 million in cash and cash equivalents.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.